Aggredyne closes $3 million Series A convertible preferred share financing Aggredyne priligy.

Aggredyne closes $3 million Series A convertible preferred share financing Aggredyne, Inc priligy ., a Houston-based biomedical diagnostics firm that is defining a new regular for platelet function tests, sold out and closed a $3 million Series A convertible recommended stock financing. Aggredyne is also getting ready to file with the meals and Medication Administration a 510 for clearance to market its initial item, the AggreGuideTM A-100, and related bloodstream platelet assessment. The AggreGuide is usually a patented, simple, inexpensive, laser-light-scattering platelet aggregometer that quickly analyzes a patient’s responsiveness to his anti-platelet medication.

‘This enterprise view enables clinicians to make faster and more informed decisions based on more complete individual information, leading to improved delivery of patient care and attention.’ Integration unites OnBase, an industry-leading enterprise articles management option, with Agfa HealthCare's imaging clinical info system , connecting individual medical information and medical images within the EHR Joint alternative provides real-time access to a affected person's full medical history across the hospital enterprise, enhancing care and decision-making while lowering costs To arrange your individual demonstration and discussion, please visit or.. Agfa Health care Corp. And OnBase by Hyland integrate best-in-class business imaging and enterprise content management technologies to optimize the EHR Agfa HealthCare Corp.

Copyright 2018